PMID- 21525722
OWN - NLM
STAT- MEDLINE
DCOM- 20120117
LR  - 20110913
IS  - 1423-0399 (Electronic)
IS  - 0042-1138 (Linking)
VI  - 87
IP  - 2
DP  - 2011
TI  - Expression of ERbeta and its co-regulators p300 and NCoR in human transitional cell 
      bladder cancer.
PG  - 151-8
LID - 10.1159/000324262 [doi]
AB  - OBJECTIVE: Several data support a possible role of estrogens in bladder 
      carcinogenesis, mediated mainly through estrogen receptor-beta (ERbeta). We study the 
      expression of ERbeta and its co-regulators p300 and nuclear co-repressor (NCoR) in 
      patients with bladder cancer. PATIENTS AND METHODS: One hundred and eleven 
      consecutive patients (74 males and 37 females), aged 23-90 years (mean 70 +/- 10) 
      diagnosed with transitional cell bladder cancer were included in this study. The 
      control group consisted of 29 patients that underwent transurethral prostatectomy 
      and consented to simultaneous bladder biopsies. Immunohistochemical studies took 
      place on formalin-fixed, paraffin-embedded sections from the TUR (transurethral 
      resection) specimens. We studied the expression of ERbeta, p300 and NCoR.chi(2) test 
      was used to evaluate the relationship between the histological grade and ERbeta 
      expression, grade and co-regulators expression and grade and gender. Spearman 
      rank correlation coefficient (r) was used in order to estimate the direction and 
      strength of correlations between histological grade and ERbeta-p300-NCoR 
      expressions. The Cochran-Armitage test for trend was applied in order to examine 
      possible trends across the ordered levels of histological grade. RESULTS: ERbeta was 
      more frequently expressed in the nucleus of normal bladder epithelium compared to 
      malignant bladder epithelium with statistical significant association (r = -0.25, 
      p = 0.003). The p300 was expressed only in the nucleus of bladder cancer cells 
      and a positive correlation between molecular expression and cancer progression 
      was demonstrated (r = 0.55, p < 0.001). NCoR immunostaining was demonstrated in 
      the nuclei of bladder cells. Nuclear staining was significantly higher in normal 
      tissue than in cancer cells (r = -0.33, p < 0.001), with negative correlation. 
      Furthermore, its expression in grade I tumors was significantly higher than in 
      grade II (r = -0.46, p < 0.001) and grade III tumors (r = -0.51, p < 0.001). 
      Thus, like ERbeta, NCoR expression in bladder epithelium decreased during cancer 
      progression and loss of cell differentiation. There was no correlation between 
      the levels of expression of the three proteins in normal bladder epithelium, but 
      there was an inverse correlation between the nuclear expression of ERbeta and p300 
      in carcinomas (r = -3.88, p = 0.042). Statistical significant association was 
      established when correlating ERbeta expression with NCoR expression (r = 0.273, p = 
      0.005), while co-regulators' nuclear expression did not correlate with each other 
      (p > 0.05). CONCLUSIONS: In bladder carcinogenesis, we demonstrated inhibition in 
      the expression of ERbeta and its co-repressor NCoR as well as increased expression 
      of the co-activator p300.
CI  - Copyright (c) 2011 S. Karger AG, Basel.
FAU - Kontos, Stylianos
AU  - Kontos S
AD  - Department of Anatomy and Histology, School of Medicine, University of Patras, 
      Patras, Greece.
FAU - Papatsoris, Athanasios
AU  - Papatsoris A
FAU - Kominea, Athina
AU  - Kominea A
FAU - Melachrinou, Maria
AU  - Melachrinou M
FAU - Tanoglidi, Anna
AU  - Tanoglidi A
FAU - Kachrilas, Stefanos
AU  - Kachrilas S
FAU - Karavitakis, Markos
AU  - Karavitakis M
FAU - Balampani, Eleni
AU  - Balampani E
FAU - Sotiropoulou-Bonikou, Georgia
AU  - Sotiropoulou-Bonikou G
LA  - eng
PT  - Journal Article
DEP - 20110422
PL  - Switzerland
TA  - Urol Int
JT  - Urologia internationalis
JID - 0417373
RN  - 0 (Estrogen Receptor beta)
RN  - 0 (NCOR1 protein, human)
RN  - 0 (Nuclear Receptor Co-Repressor 1)
RN  - EC 2.3.1.48 (E1A-Associated p300 Protein)
RN  - EC 2.3.1.48 (EP300 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Transitional Cell/*metabolism
MH  - Disease Progression
MH  - E1A-Associated p300 Protein/*biosynthesis
MH  - Epithelium/pathology
MH  - Estrogen Receptor beta/*biosynthesis
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nuclear Receptor Co-Repressor 1/*biosynthesis
MH  - Prognosis
MH  - Urinary Bladder Neoplasms/*metabolism
EDAT- 2011/04/29 06:00
MHDA- 2012/01/18 06:00
CRDT- 2011/04/29 06:00
PHST- 2010/07/27 00:00 [received]
PHST- 2011/01/04 00:00 [accepted]
PHST- 2011/04/29 06:00 [entrez]
PHST- 2011/04/29 06:00 [pubmed]
PHST- 2012/01/18 06:00 [medline]
AID - 000324262 [pii]
AID - 10.1159/000324262 [doi]
PST - ppublish
SO  - Urol Int. 2011;87(2):151-8. doi: 10.1159/000324262. Epub 2011 Apr 22.